We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.


registration required

for more website access

This content can only be viewed by subscribers and registered users of Investors Chronicle.

Subscribe or register free today

Dechra's high price defence

Dechra Pharmaceuticals (DPH) spent most of the first half integrating its €135m (£110m) Eurovet acquisition. That should ultimately mean cost savings totalling £4m through the rationalisation of different manufacturing sites. However, Dechra's performance will be weighted to the second half of the year, as it deals with a variety of operational issues in its main business divisions that have arisen from its acquisition strategy.

registration required

visible-status-Standard story-url-Dechra Pharma interims 2013 260213.xml

By Julian Hofmann,
26 February 2013

Print this article

Related Companies

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply